Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug

Bibliography

• PETTIT GR, HERALD CL, DOUBEK DL et al.: Isolation andstructure of bryostatin 1. J. Am. Chem. Soc. (1982) 104:6846–6848.
   Web of Science ®Google Scholar
• CHEUNG AP, HALLOCK YF, VISHNUVAJJALA BR,NGUYENLE T: Compatibility and stability of bryostatin 1 in infusion devices. Invest. New Drugs (1998) 16:227–236.
   PubMed Web of Science ®Google Scholar
• PHILIP PA, HARRIS AL: Potential for protein kinase Cinhibitors in cancer therapy. In: Concepts, Mechanisms, and New Targets for Chemotherapy Muggia FM (Ed.) (1995):3–27.
   Google Scholar
• ••A review article on the emerging role of protein kinase Cmodulation in cancer therapy.
   Google Scholar
• NISHIZUKA Y: The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature (1984) 308:693–698.
   PubMed Web of Science ®Google Scholar
• NISHIZUKA Y: The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. J. Am. Med. Assoc. (1989) 262:1826–1833.
   PubMed Web of Science ®Google Scholar
• STABEL S, PARKER PJ: Protein kinase C. Pharmacol Ther. (1991) 51:71–95.
   PubMed Web of Science ®Google Scholar
• STABEL S: Protein kinase C-an enzyme and its relatives. Semin. Cancer Biol. (1994) 5:277–284.
   PubMed Web of Science ®Google Scholar
• AZZI A, BOSCOBOINIK D, HENSEY C: The protein kinase C family. Eur. J. Biochem. (1992) 208:547–557.
   PubMedGoogle Scholar
• KISHIMOTO A, TAKAI Y, MORI T, KIKKAWA U, NISHIZUKA Y: Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidyli-nositol turnover. J. Biol. Chem. (1980) 255:2273–2276.
   PubMed Web of Science ®Google Scholar
• O'BRIAN CA, WARD NE: Biology of the protein kinase C family. [Review]. Cancer Metastasis Rev. (1989) 8:199–214.
   PubMed Web of Science ®Google Scholar
• KRAFT AS, SMITH JB, BERKOW RL: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differen-tiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. USA (1986) 83:1334–1338.
   PubMed Web of Science ®Google Scholar
• HENNINGS H, BLUMBERG PM, PETTIT GR et al.: Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (1987) 8:1343–1346.
   PubMed Web of Science ®Google Scholar
• MAY WS, SHARKIS SJ, ESA AH et al.: Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA (1987) 84:8483–8487.
   PubMed Web of Science ®Google Scholar
• HEYWORTH CM, DEXTER TM, NICHOLLS SE, WHETTON AD: Protein kinase C activators can interact synergisti-cally with granulocyte colony-stimulating factor or interleukin-6 to stimulate colony formation from enriched granulocyte-macrophage colony-forming cells. Blood (1993) 81:894–900.
   PubMed Web of Science ®Google Scholar
• LI F, GRANT S, PETTIT GR, MCCRADY CW: Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony- stimulating factor. Blood (1992) 80:2495–2502.
   PubMed Web of Science ®Google Scholar
• GEBBIA V, GEBBIA N, RAUSA L, SHARKIS SJ, MAY WS: In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1. Pharmacol. Res. (1990) 22 (Suppl. 0:103–4.
   Google Scholar
• SHARKIS SJ, JONES RJ, BELLIS ML et al. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood (1990) 76:716–720.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, MAY WS, IHLE JN, PETTIT GR, SHARKIS SJ: Regulation of hematopoiesis-IV: The role of interleukin-3 and bryostatin 1 in the growth of erythropoietic progenitors from normal and anemic W/Wv mice. Blood (1988) 72:1492–1496.
   PubMed Web of Science ®Google Scholar
• LILLY M, VO K, LE T, TAKAHASHI G: Bryostatin 1 acts synergistically with interleukin-1 ?to induce secretion of G-CSF and other cytokines from marrow stromal cells. Exp. Hematol. (1996) 24:613–621.
   PubMed Web of Science ®Google Scholar
• DRAGER AM, VAN DER HEM KG, ZEVENBERGEN A et al.: Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis. Leukemia (1999) 13:62–69.
   Google Scholar
• EISEMANN K, TOTOLA A, JURCIC K, PETTIT GR, WAGNER H: Bryostatins 1,2 and 5 activate human granulocytes and lymphocytes: in vitro and in vivo studies. Pharm. Pharmacol. Lett. (1995) 1,45–48.
   Google Scholar
• TRENN G, PETTIT GR, TAKAYAMA H, HU-LI J, SITKOVSKY MV: Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J. Immunol. (1988) 140:433–439.
   PubMed Web of Science ®Google Scholar
• ••Highlights the potential use of bryostatin 1 as an immunemodulator in the immunotherapy of cancers.
   Google Scholar
• HESS AD, SILANSKIS MK, ESA AH, PETTIT GR, MAY WS: Activation of human T lymphocytes by bryostatin. J. Immunol. (1988) 141:3263–3269.
   PubMed Web of Science ®Google Scholar
• ESA AH, BOTO WO, ADLER WH, MAY WS, HESS AD: Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors. Int. J. Immuno-pharmacol. (1990) 12:481–490.
   PubMed Web of Science ®Google Scholar
• TUTTLE TM, BETHKE KP, INGE TH et al.: Bryostatin 1-activated T cells can traffic and mediate tumor regression. J. Surg. Res. (1992) 52:543–548.
   PubMed Web of Science ®Google Scholar
• TUTTLE TM, INGE TH, WIRT CP et al.: Bryostatin 1 activates T cells that have antitumor activity. J. Immunother. (1992) 12:75–81.
   PubMed Web of Science ®Google Scholar
• TUTTLE TM, INGE TH, BETHKE KP et al.: Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res. (1992) 52:548–553.
   PubMed Web of Science ®Google Scholar
• TILDEN AB, KRAFT AS: The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity. J. Immuno-ther. (1991) 10:96–104.
   PubMed Web of Science ®Google Scholar
• BERKOW RL, KRAFT AS: Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymor-phonuclear leukocytes and binds to the phorbol ester receptor. Biochem. Biophys. Res. Comm. (1985) 131:1109–1116.
   PubMed Web of Science ®Google Scholar
• ESA AH, WARREN JT, HESS AD, MAY WS: Bryostatinstrigger human polymorphonuclear neutrophil and monocyte oxidative metabolism: association with in vitro antineoplastic activity. Res. Immunol. (1995) 146:351–361.
   PubMedGoogle Scholar
• BERKOW RL, SCHLABACH L, DODSON R et al. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. (1993) 53:2810–2815.
   PubMed Web of Science ®Google Scholar
• CARR ME, JR, CARR SL, GRANT S: A sensitive plateletactivation-based functional assay for the antileukemic agent bryostatin 1. AntiCancer Drugs (1995) 6:384–391.
   PubMed Web of Science ®Google Scholar
• GRABAREK J, WARE J A: Protein kinase C activationwithout membrane contact in platelets stimulated by bryostatin. J. Biol. Chem. (1993) 268:5543–5549.
   PubMed Web of Science ®Google Scholar
• BOSCO MC, ROTTSCHAFER S, TAYLOR LS et al.: The antineoplastic agent bryostatin-1 induces proinflam-matory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2R gamma chain expression. Blood (1997) 89:3402–3411.
   PubMed Web of Science ®Google Scholar
• STEUBE KG, DREXLER HG: Differentiation and growthmodulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1. [Review] [90 refs]. Leuk. Lymphoma (1993) 9:141–148.
   PubMed Web of Science ®Google Scholar
• STONE R M, SARIBAN E, PETTIT G R, KUFE D W: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood (1988) 72:208–213.
   PubMed Web of Science ®Google Scholar
• HU ZB, MA W, UPHOFF CC, LANOTTE M, DREXLER HG:Modulation of gene expression in the acute promyelo-cytic leukemia cell line NB4. Leukemia (1993) 7: 1817-1823.
   Google Scholar
• SONG X, SHEPPARD HM, NORMAN AW, LIU X: Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentia-tion of the acute promyelocytic leukemia NB4 cell line. J. Biol. Chem. (1999) 274:1677–1682.
   PubMed Web of Science ®Google Scholar
• VRANA JA, RAO AS, WANG Z, JARVIS WD, GRANT S: Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure. Int. J. Oncol. (1998) 12:927–934.
   PubMed Web of Science ®Google Scholar
• GRANTS, PETTIT GR, HOWE C, MCCRADY C: Effect of theprotein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor. Leukemia (1991) 5:392–398.
   PubMed Web of Science ®Google Scholar
• KRAFT AS, WILLIAM F, PETTIT GR, LILLY MB: Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. (1989) 49:1287–1293.
   PubMed Web of Science ®Google Scholar
• JONES R J, SHARKIS S J, MILLER C B eta].: Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood (1990) 75,1319–1323.
   Google Scholar
• AL-KATIB A, MOHAMMAD R M, DAN M et al.: Bryostatin1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. (1993) 21:61–65.
   PubMed Web of Science ®Google Scholar
• GEBBIA V, CITARRELLA P, MISERENDINO V et al.: Theeffects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro. Tumouri (1992) 78:167–171.
   PubMed Web of Science ®Google Scholar
• HU ZB, GIGNAC SM, UPHOFF CC et al.: Induction ofdifferentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1. Leukemia Lymph. (1993) 10:135–142.
   PubMed Web of Science ®Google Scholar
• DREXLER HG, GIGNAC SM, JONES RA et al.: Bryostatin 1induces differentiation of B-chronic lymphocytic leukemia cells. Blood (1989) 74: 1747-1757.
   Google Scholar
• AL-KATIB A, MOHAMMAD RM, MOHAMED AN, PETTIT GR, SENSENBRENNER LL: Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol Oncol. (1990) 8:81–89.
   PubMed Web of Science ®Google Scholar
• MOHAMMAD RM, AL-KATIB A, PETTIT GR, SENSEN-BRENNER LL: Differential effects of bryostatin 1 on human non-Hodgkin's B- lymphoma cell lines. Leukemia Res. (1993) 17:1–8.
   PubMed Web of Science ®Google Scholar
• MOHAMMAD RM, AL-KATIB A, PETTIT GR, SENSEN-BRENNER LL: Successful treatment of human Walden-strom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res. (1994) 54:165–168.
   PubMed Web of Science ®Google Scholar
• KENNEDY MJ, PRESTIGIACOMO LJ, TYLER G, MAY WS,DAVIDSON NE: Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. (1992) 52:1278–1283.
   PubMed Web of Science ®Google Scholar
• STANWELL C, GESCHER A, BRADSHAW TD, PETTIT GR:The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int. J. Cancer (1994) 56:585–592.
   PubMed Web of Science ®Google Scholar
• WANG S, GUO CY, CASTILLO A, DENT P, GRANTS: Effectof bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem. Pharmacol. (1998) 56:635–644.
   PubMed Web of Science ®Google Scholar
• DALE IL, GESCHER A: Effects of activators of proteinkinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int. J. Cancer (1989) 43:158–163.
   PubMed Web of Science ®Google Scholar
• BRADSHAW TD, GESCHER A, PETTIT GR: Modulation bystaurosporine of phorbol-ester-induced effects on growth and protein kinase C localization in A549 human lung-carcinoma cells. Int. J. Cancer (1992) 51:144–148.
   PubMed Web of Science ®Google Scholar
• HORNUNG RL, PEARSON JW, BECKWITH M, LONGO DL: Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. (1992) 52:101–107.
   PubMed Web of Science ®Google Scholar
• ••Presents the preclinical data on the anticancer effects ofbryostatin 1 that stimulated its development in the treatment of human cancers.
   Google Scholar
• MAPELLI E, BANFI P, SALA E et al.: Effect of proteinkinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes. Int. J. Cancer (1994) 57:281–286.
   PubMed Web of Science ®Google Scholar
• SCHUCHTER LM, ESA AH, MAY S et al.: Successfultreatment of murine melanoma with bryostatin 1. Cancer Res. (1991) 51:682–687.
   PubMed Web of Science ®Google Scholar
• ELGIE AW, SARGENT JM, ALTON P et al.: Modulation ofresistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leukemia Res. (1998) 22:373–378.
   PubMed Web of Science ®Google Scholar
• GRANT S: Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1. Front Biosci. (1997) 2:242–252.
   Google Scholar
• ••Presents an important synergistic interaction betweenbryostatin 1 and ara-C.
   Google Scholar
• WANG S, VRANA JA, BARTIMOLE TM et al.: Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bc1-2. Mol. Pharmacol. (1997) 52:1000–1009.
   PubMed Web of Science ®Google Scholar
• VRANA JA, RAO AS, WANG Z, JARVIS WD, GRANT S: Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure. Int. J. Oncol. (1998) 12:927–934.
   PubMed Web of Science ®Google Scholar
• MOHAMMAD RM, BECK FW, KATATO K et al.: Potentia-tion of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bc1-2. Biol. Chem. (1998) 379:1253–1261.
   PubMed Web of Science ®Google Scholar
• WANG Z, SU ZZ, FISHER PB et al.: Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells. Exp. Cell Res. (1998) 244:105–116.
   PubMed Web of Science ®Google Scholar
• BASU A, EVANS RW: Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis- diamminedichloroplatinum(I). Int. J. Cancer (1994) 58:587–591.
   PubMed Web of Science ®Google Scholar
• AL-KATIB AM, SMITH MR, KAMANDA WS et al.: Bryostatin 1 down-regulates mdrl and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res. (1998) 4:1305–1314.
   PubMed Web of Science ®Google Scholar
• SPITALER M, UTZ I, HILBE W, HOFMANN J, GRUNICKE H H: PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem. Pharmacol. (1998) 56:861–869.
   PubMed Web of Science ®Google Scholar
• SCALA S, DICKSTEIN B, REGIS J, SZALLASI Z, BATES S E:Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin. Cancer Res. (1995) 1:1581–1587.
   PubMed Web of Science ®Google Scholar
• O'BRIAN CA, LISKAMP RM, SOLOMON DH, WEINSTEIN IB: Inhibition of protein kinase C by tamoxifen. Cancer Res. (1985) 45:2462–2465.
   PubMed Web of Science ®Google Scholar
• MCGOWN AT, JAYSON G, PETTIT GR et al. Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br. J. Cancer (1998) 77:216–220.
   PubMed Web of Science ®Google Scholar
• MOHAMMAD RM, VARTERASIAN ML, ALMATCHY VP eta].:Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin. Cancer Res. (1998) 4:1337–1343.
   Google Scholar
• MAKI A, DIWAKARAN H, REDMAN B eta].: The bc1-2 andp53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. AntiCancer Drugs (1995) 6:392–397.
   Google Scholar
• MOHAMMAD RM, PETTIT GR, ALMATCHY VP et al.: Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. AntiCancer Drugs (1998) 9:149–156.
   PubMed Web of Science ®Google Scholar
• GRANTS, PETTIT GR, MCCRADY C: Effect of bryostatin 1on the in vitro radioprotective capacity of recombi-nant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM). Exp. Hematol. (1992) 20:34–42.
   PubMed Web of Science ®Google Scholar
• KALECHMAN Y, ALBECK M, SREDNI B: In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Cell. Immunol. (1992) 143:143–153.
   PubMed Web of Science ®Google Scholar
• GRANTS, TRAYLOR R, PETTIT GR, UN PS: Modulation bybryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors. Cytokine (1993) 5:490–497.
   PubMed Web of Science ®Google Scholar
• WATSON NC, JARVIS WD, ORR MS, GRANT S, GEWIRTZDA: Radiosensitization of HL-60 human leukaemia cells by bryostatin- 1 in the absence of increased DNA fragmentation or apoptotic cell death. Int. J. RadiaL Biol. (1996) 69,183–192.
   PubMed Web of Science ®Google Scholar
• PHILIP PA, REA D, THAVASU P et al.: Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee [see comments]. J. Nati Cancer Inst. (1993) 85:1812–1818.
   Google Scholar
• ••This paper represents early human experience withbryostatin 1 in the Phase I setting. The dose-limiting toxicities were determined in this study. Release of cytokines was shown to occur in patients treated with this drug.
   Google Scholar
• PRENDIVILLE J, CROWTHER D, THATCHER N et al.: APhase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer (1993) 68:418–424.
   PubMed Web of Science ®Google Scholar
• JAYSON GC, CROWTHER D, PRENDIVILLE J et al.: A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer (1995) 72:461–468.
   PubMed Web of Science ®Google Scholar
• SCHEID C, PRENDIVILLE J, JAYSON G et al: Immuno-modulation in patients receiving intravenous Bryostatin 1 in a Phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol. Immunother. (1994) 39:223–230.
   PubMed Web of Science ®Google Scholar
• VARTERASIAN ML, MOHAMMAD RM, EILENDER DS et al: Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol. (1998) 16:56–62.
   PubMed Web of Science ®Google Scholar
• GRANT S, ROBERTS J, POPLIN E et al: Phase lb trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res. (1998) 4:611–618.
   PubMed Web of Science ®Google Scholar
• KHAN P, MCGOWN AT, DAWSON MJ et al.: High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J. Chromatogr. B. Biomed. Appl. (1998) 709:113–117.
   PubMed Web of Science ®Google Scholar
• KAUBISCH A, KELSEN DP, SALTZ L et al.: A Phase! trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors. Proc. ASCO (1999) 18:639.
   Google Scholar
• ROSENTHAL MA, ORATZ R, LIEBES L, CAHR MH, MUGGIA FM: Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies. Proc. ASCO (1999) 18:873.
   Google Scholar
• PROPPER DJ, MACAULAYV, O'BYRNE KJ et al.: A Phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer (1998) 78:1337–1341.
   Google Scholar
• BEDIKIAN A, PLAGER C, PAPADOPOULOS N et al.: Phase II trial of bryostatin-1 in patients with melanoma. Proc. ASCO (1999) 18:2051
   Google Scholar
• TOZER RG, BURDETTE-RADOUX S, BELANGER K et al: NCIC CTG randomized Phase II study of two schedules of bryostatin 1 (N5C339555) in patients with advanced malignant melanoma (IND.104). Proc. ASCO (1999) 18:2052.
   Google Scholar
• HICKMAN PF, KEMP GJ, THOMPSON CH et al.: Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectro-scopic study. Br. J. Cancer (1995) 72:998–1003.
   PubMed Web of Science ®Google Scholar
• THOMPSON C H, MACAULAY V M, O'BYRNE K J et al.: Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br. J. Cancer (1996) 73:1161-1165. Jeffrey A Zonder & Philip A Philipt tAuthor for correspondence Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, 509 Hudson Building, 3990 John R St., Detroit, MI48201, USA Tel.: +1 313 745 9155; Fax: +1 313 993 0559; E-mail: [email protected]
   Google Scholar